{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:58:00Z","timestamp":1787313480988,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"RSJS, RCR and VEAO received a scholarship from CONAHCYT for their PhD education while working on this research."},{"name":"Programa de Fortalecimiento de la Investigaci\u00f3n y el Posgrado 2022. Universidad de Guadalajara."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75458-2","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T07:03:10Z","timestamp":1729494190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["H3K9me3 demethylation by JMJD2B is regulated by pirfenidone resulting in improved NASH"],"prefix":"10.1038","volume":"14","author":[{"given":"J. Samael","family":"Rodriguez-Sanabria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Rosas-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"V\u00e1zquez-Esqueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne","family":"Palacios-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Jim\u00e9nez-Chillaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Escutia-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Jave-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Galicia-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo Christian","family":"Monroy-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eira","family":"Cerda-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Almeida-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Martinez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Alonso","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Armend\u00e1riz-Borunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sandoval-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"75458_CR1","unstructured":"NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78(6), 1966\u20131986 (2023)."},{"key":"75458_CR2","doi-asserted-by":"crossref","unstructured":"Stephen, A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. New. Engl. J. Med. Febr. 390(6), 497\u2013509 (2024) (for the MAESTRO-NASH Investigators).","DOI":"10.1056\/NEJMc2402905"},{"issue":"10290","key":"75458_CR3","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397(10290), 2212\u20132224 (2021).","journal-title":"Lancet"},{"issue":"5","key":"75458_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt, M. J. et al. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr. Rev. 40(5), 1367\u20131393 (2019).","journal-title":"Endocr. Rev."},{"issue":"3","key":"75458_CR5","first-page":"434","volume":"16","author":"SR Ana","year":"2020","unstructured":"Ana, S. R. et al. Pirfenidone is an agonistic ligand for PPAR\u03b1 and improves NASH by activation of SIRT1\/LKB1\/pAMPK. Hepatol. Commun. 16(3), 434\u2013449 (2020).","journal-title":"Hepatol. Commun."},{"issue":"1","key":"75458_CR6","doi-asserted-by":"publisher","first-page":"11709","DOI":"10.1038\/s41598-021-91187-2","volume":"11","author":"R Escutia-Guti\u00e9rrez","year":"2021","unstructured":"Escutia-Guti\u00e9rrez, R. et al. Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD\/NASH. Sci. Rep. 11(1), 11709 (2021).","journal-title":"Sci. Rep."},{"key":"75458_CR7","doi-asserted-by":"crossref","unstructured":"Kim, J. H. et al. Histone H3K9 demethylase JMJD2B induces hepatic steatosis through upregulation of PPAR\u03b32. Sci. Rep.8(1)  (2018).","DOI":"10.1038\/s41598-018-31953-x"},{"issue":"21","key":"75458_CR8","doi-asserted-by":"publisher","first-page":"8313","DOI":"10.3390\/ijms21218313","volume":"21","author":"JH Kim","year":"2020","unstructured":"Kim, J. H. et al. Histone H3K9 demethylase JMJD2B plays a role in LXR\u03b1-dependent lipogenesis. Int. J. Mol. Sci. 21(21), 8313 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"75458_CR9","doi-asserted-by":"publisher","first-page":"770504","DOI":"10.3389\/fmed.2021.770504","volume":"8","author":"JS Rodr\u00edguez-Sanabria","year":"2022","unstructured":"Rodr\u00edguez-Sanabria, J. S. et al. An update in epigenetics in metabolic-associated fatty liver disease. Front. Med. (Lausanne) 8, 770504 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"75458_CR10","doi-asserted-by":"crossref","unstructured":"Ramon-Krauel, M. et al. Epigenetic programming at the Mogat1 locus may link neonatal overnutrition with long-term hepatic steatosis and insulin resistance. FASEB J. fj201700717RR (2018).","DOI":"10.1096\/fj.201700717RR"},{"issue":"36","key":"75458_CR11","doi-asserted-by":"publisher","first-page":"eabg9241","DOI":"10.1126\/sciadv.abg9241","volume":"7","author":"Y Xi","year":"2021","unstructured":"Xi, Y. et al. The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1. Sci. Adv. 7(36), eabg9241 (2021).","journal-title":"Sci. Adv."},{"key":"75458_CR12","doi-asserted-by":"publisher","first-page":"44754","DOI":"10.1038\/srep44754","volume":"7","author":"C Komiya","year":"2017","unstructured":"Komiya, C. et al. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci. Rep. 7, 44754 (2017).","journal-title":"Sci. Rep."},{"key":"75458_CR13","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1136\/gut.2006.107136","volume":"55","author":"J Armend\u00e1riz-Borunda","year":"2006","unstructured":"Armend\u00e1riz-Borunda, J. et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 55, 1663\u20131665 (2006).","journal-title":"Gut"},{"issue":"9","key":"75458_CR14","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1016\/j.sjbs.2021.06.079","volume":"28","author":"F Noor","year":"2021","unstructured":"Noor, F. et al. Construction of miRNA-mRNA network for the identification of key biological markers and their associated pathways in IgA nephropathy by employing the integrated bioinformatics analysis. Saudi J. Biol. Sci. 28(9), 4938\u20134945 (2021).","journal-title":"Saudi J. Biol. Sci."},{"issue":"1","key":"75458_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/hep.25609","volume":"56","author":"J Lee","year":"2012","unstructured":"Lee, J. et al. Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice. Hepatology 56(1), 108\u2013117 (2012).","journal-title":"Hepatology"},{"issue":"6","key":"75458_CR16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jhep.2013.05.039","volume":"59","author":"M Zeybel","year":"2013","unstructured":"Zeybel, M., Mann, D. A. & Mann, J. Epigenetic modifications as new targets for liver disease therapies. J. Hepatol. 59(6), 1349\u20131353 (2013).","journal-title":"J. Hepatol."},{"issue":"4","key":"75458_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides, T. Chromatin modifications and their function. Cell 128(4), 693\u2013705 (2007).","journal-title":"Cell"},{"issue":"12","key":"75458_CR18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1101\/gad.388206","volume":"20","author":"BD Fodor","year":"2006","unstructured":"Fodor, B. D. et al. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev. 20(12), 1557\u20131562 (2006).","journal-title":"Genes Dev."},{"key":"75458_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","volume":"21","author":"AJ Bannister","year":"2011","unstructured":"Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 21, 381\u2013395 (2011).","journal-title":"Cell Res."},{"issue":"5532","key":"75458_CR20","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1126\/science.1063127","volume":"293","author":"T Jenuwein","year":"2001","unstructured":"Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293(5532), 1074\u20131080 (2001).","journal-title":"Science"},{"issue":"3","key":"75458_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2006.03.028","volume":"125","author":"JR Whetstine","year":"2006","unstructured":"Whetstine, J. R. et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125(3), 467\u2013481 (2006).","journal-title":"Cell"},{"issue":"1","key":"75458_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.acthis.2014.10.002","volume":"117","author":"J-W Lu","year":"2015","unstructured":"Lu, J-W. et al. JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: A tissue microarray-based study. Acta Histochem. 117(1), 14\u201319 (2015).","journal-title":"Acta Histochem."},{"issue":"4","key":"75458_CR23","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3892\/or.2015.3744","volume":"33","author":"SY Hwang","year":"2015","unstructured":"Hwang, S. Y. et al. Emodin attenuates radioresistance induced by hypoxia in HepG2 cells via the enhancement of PARP1 cleavage and inhibition of JMJD2B. Oncol. Rep. 33(4), 1691\u20131698 (2015).","journal-title":"Oncol. Rep."},{"issue":"24","key":"75458_CR24","doi-asserted-by":"publisher","first-page":"E5566","DOI":"10.1073\/pnas.1721814115","volume":"115","author":"Y Cheng","year":"2018","unstructured":"Cheng, Y. et al. KDM4B protects against obesity and metabolic dysfunction. Proc. Natl. Acad. Sci. 115(24), E5566\u2013E5575 (2018).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"75458_CR25","doi-asserted-by":"crossref","unstructured":"Kang, C. et al. JMJD2B\/KDM4B inactivation in adipose tissues accelerates obesity and systemic metabolic abnormalities. 23(9), 767\u2013777 (2018).","DOI":"10.1111\/gtc.12627"},{"issue":"6497","key":"75458_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"W Dai","year":"2020","unstructured":"Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368(6497), 1331\u20131335 (2020).","journal-title":"Science"},{"issue":"13","key":"75458_CR27","doi-asserted-by":"publisher","first-page":"9408","DOI":"10.1074\/jbc.M112.419861","volume":"288","author":"J Sayegh","year":"2013","unstructured":"Sayegh, J. et al. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J. Biol. Chem. 288(13), 9408\u20139417 (2013).","journal-title":"J. Biol. Chem."},{"key":"75458_CR28","doi-asserted-by":"publisher","first-page":"109804","DOI":"10.1016\/j.jfluchem.2021.109804","volume":"247","author":"L Brewitz","year":"2021","unstructured":"Brewitz, L. et al. Fluorinated derivatives of pyridine-2,4-dicarboxylate are potent inhibitors of human 2-oxoglutarate dependent oxygenases. J. Fluor. Chem. 247, 109804 (2021).","journal-title":"J. Fluor. Chem."},{"issue":"11","key":"75458_CR29","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.3390\/cells9112367","volume":"9","author":"N Wagner","year":"2020","unstructured":"Wagner, N. & Wagner, K. D. The role of PPARs in disease. Cells 9(11), 2367 (2020).","journal-title":"Cells"},{"key":"75458_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.phrs.2016.02.028","volume":"111","author":"S Wang","year":"2016","unstructured":"Wang, S., Dougherty, E. J. & Danner, R. L. PPAR\u03b3 signaling and emerging opportunities for improved therapeutics. Pharmacol. Res. 111, 76\u201385 (2016).","journal-title":"Pharmacol. Res."},{"issue":"5","key":"75458_CR31","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","volume":"161","author":"R Loomba","year":"2021","unstructured":"Loomba, R. et al. TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology 161(5), 1475\u20131486 (2021).","journal-title":"Gastroenterology"},{"issue":"5","key":"75458_CR32","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/hep.32045","volume":"74","author":"Y Hu","year":"2021","unstructured":"Hu, Y. et al. Fatty acid synthase-suppressor screening identifies sorting Nexin 8 as a therapeutic target for NAFLD. Hepatology 74(5), 2508\u20132525 (2021).","journal-title":"Hepatology"},{"key":"75458_CR33","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1074\/jbc.M807616200","volume":"284","author":"ZZ Li","year":"2009","unstructured":"Li, Z. Z. et al. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: Role of stearoyl-CoA desaturase. J. Biol. Chem. 284, 5637\u20135644 (2009).","journal-title":"J. Biol. Chem."},{"issue":"9","key":"75458_CR34","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41374-019-0255-4","volume":"99","author":"G Chen","year":"2019","unstructured":"Chen, G. et al. Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages. Lab. Invest. 99(9), 1335\u20131348 (2019).","journal-title":"Lab. Invest."},{"issue":"8","key":"75458_CR35","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1074\/mcp.M113.029686","volume":"12","author":"M Piazzi","year":"2013","unstructured":"Piazzi, M. et al. Phosphoinositide-specific phospholipase C \u03b2 1b (PI-PLC\u03b21b) interactome: Affinity purification-mass spectrometry analysis of PI-PLC\u03b21b with nuclear protein. Mol. Cell. Proteom. 12(8), 2220\u20132235 (2013).","journal-title":"Mol. Cell. Proteom."},{"issue":"131","key":"75458_CR36","first-page":"2","volume":"14","author":"L Flores-Contreras","year":"2024","unstructured":"Flores-Contreras, L. et al. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. BMC Gastroenterol. 14(131), 2\u201311 (2024).","journal-title":"BMC Gastroenterol."},{"issue":"5","key":"75458_CR37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s12072-020-10069-3","volume":"14","author":"JL Poo","year":"2020","unstructured":"Poo, J. L. et al. Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study. Hepatol. Int. 14(5), 817\u2013827 (2020).","journal-title":"Hepatol. Int."},{"key":"75458_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejphar.2008.06.110","volume":"24","author":"A Salazar-Montes","year":"2008","unstructured":"Salazar-Montes, A. et al. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur. J. Pharmacol. 24, 69\u201377 (2008).","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"75458_CR39","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1016\/j.sjbs.2021.07.068","volume":"28","author":"M Sufyan","year":"2021","unstructured":"Sufyan, M. et al. Identifying key genes and screening therapeutic agents associated with diabetes mellitus and HCV-related hepatocellular carcinoma by bioinformatics analysis. Saudi J. Biol. Sci. 28(10), 5518\u20135525 (2021).","journal-title":"Saudi J. Biol. Sci."},{"key":"75458_CR40","doi-asserted-by":"crossref","unstructured":"Noor, F. et al. Comprehensive computational analysis reveals H5N1 influenza virus-encoded miRNAs and host-specific targets associated with antiviral immune responses and protein binding. PloS One 17(5), e0263901. (2022).","DOI":"10.1371\/journal.pone.0263901"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75458-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75458-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75458-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T11:07:41Z","timestamp":1729768061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75458-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75458"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75458-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ABJ is consultant for Cellpharma. Rest of authors have nothing to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24714"}}